

PharMerica CORP  
Form 8-K  
August 02, 2013

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, DC 20549

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of  
the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): August 2, 2013**

**PHARMERICA CORPORATION**

(Exact Name of Registrant as Specified in Its Charter)

**Delaware**  
(State or Other Jurisdiction  
  
of Incorporation)

**001-33380**  
(Commission  
  
File Number)

**87-0792558**  
(IRS Employer  
  
Identification No.)

Edgar Filing: PharMerica CORP - Form 8-K

**1901 Campus Place**

**Louisville, Kentucky**  
(Address of principal executive offices)

**40299**  
(Zip Code)

**(502) 627-7000**

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 2.02 Results of Operations and Financial Condition.**

On August 2, 2013, PharMerica Corporation (the Company) issued a press release announcing results of operations for the second quarter ended June 30, 2013, a copy of which is attached as Exhibit 99.1.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits

99.1 Press Release of PharMerica Company dated August 2, 2013.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**PHARMERICA CORPORATION**

Date: August 2, 2013

By: /s/ Thomas A. Caneris  
Thomas A. Caneris  
Senior Vice President, General Counsel, Chief

Compliance Officer and Secretary

**Exhibit Index**

**Exhibit**

<b>No.</b>	<b>Description</b>
99.1	Press Release of PharMerica Company dated August 2, 2013.